FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda; Merck & Co., Inc., https://www.merck.com) for treatment of patients with metastatic non‐small cell lung cancer (mNSCLC) whose tumors express programmed death‐ligand 1 (PD‐L1) as determined by an FD...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai‐Scherf, Lee, Blumenthal, Gideon M., Li, Hongshan, Subramaniam, Sriram, Mishra‐Kalyani, Pallavi S., He, Kun, Zhao, Hong, Yu, Jingyu, Paciga, Mark, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679831/
https://www.ncbi.nlm.nih.gov/pubmed/28835513
http://dx.doi.org/10.1634/theoncologist.2017-0078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679831/
https://www.ncbi.nlm.nih.gov/pubmed/28835513
http://dx.doi.org/10.1634/theoncologist.2017-0078

Ejemplares similares